📊 OMDA Key Takeaways
Is Omada Health, Inc. (OMDA) a Good Investment?
Omada Health demonstrates strong revenue acceleration (53.2% YoY) with exceptional unit economics (65.7% gross margin) and a fortress balance sheet ($222M cash, zero debt). The company is rapidly approaching profitability with net losses improving 72.9% YoY while maintaining positive free cash flow, indicating quality growth and near-term path to sustained profitability.
Omada Health is scaling rapidly with 53% YoY revenue growth, a 66% gross margin, and positive free cash flow, indicating a capital-light model with improving unit economics. Losses are modest and narrowing, and a debt-free, cash-rich balance sheet provides ample runway to reach sustained GAAP profitability. Continued execution should translate operating leverage into durable profits while maintaining growth quality.
Why Buy Omada Health, Inc. Stock? OMDA Key Strengths
- Exceptional revenue growth of 53.2% YoY demonstrates strong market demand
- Excellent gross margin of 65.7% shows strong unit economics and pricing power
- Fortress balance sheet with $222M cash (73% of total assets), zero debt, and 3.60x current ratio provides significant runway
- Positive free cash flow of $16.9M despite net losses indicates high-quality business model
- Rapidly improving profitability with net loss reducing 72.9% YoY, showing trajectory toward breakeven
- Debt-free balance sheet with $222M cash and strong liquidity (3.6x current ratio)
- Positive operating and free cash flow with low capex (6.5% FCF margin)
- High gross margin (65.7%) and improving operating leverage near breakeven
OMDA Stock Risks: Omada Health, Inc. Investment Risks
- Currently unprofitable with operating loss of $12.0M and net loss of $12.8M - path to sustained profitability not yet proven
- Negative operating margin (-4.6%) and net margin (-4.9%) indicate company is scaling faster than cost structure allows
- Significant insider Form 4 activity (15 filings in 90 days) may signal uncertainty among company insiders
- Health services sector is competitive with pricing pressure and regulatory risk not fully apparent in financials
- Dependency on continued high growth rates to reach profitability - growth deceleration would extend breakeven timeline
- Potential revenue growth deceleration as scale increases
- Regulatory/reimbursement and payer contract risks affecting revenue visibility
- Competitive digital health market and possible customer concentration pressuring margins/retention
Key Metrics to Watch
- Operating margin trajectory and timeline to breakeven
- Revenue growth sustainability as customer base scales
- Operating cash flow conversion rate and cash burn runway
- Customer acquisition costs and lifetime value economics in SEC filings
- Operating margin (sustained positive, >5%)
- Revenue growth YoY (sustainability >25%)
Omada Health, Inc. (OMDA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.60x current ratio provides a solid financial cushion.
OMDA Profit Margin, ROE & Profitability Analysis
OMDA vs Services Sector: How Omada Health, Inc. Compares
How Omada Health, Inc. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Omada Health, Inc. Stock Overvalued? OMDA Valuation Analysis 2026
Based on fundamental analysis, Omada Health, Inc. has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Omada Health, Inc. Balance Sheet: OMDA Debt, Cash & Liquidity
OMDA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Omada Health, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-9.52 indicates the company is currently unprofitable.
OMDA Revenue Growth, EPS Growth & YoY Performance
OMDA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $45.5M | -$3.2M | $-0.06 |
| Q2 2025 | $41.2M | -$5.3M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Omada Health, Inc. Dividends, Buybacks & Capital Allocation
OMDA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Omada Health, Inc. (CIK: 0001611115)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OMDA
What is the AI rating for OMDA?
Omada Health, Inc. (OMDA) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are OMDA's key strengths?
Claude: Exceptional revenue growth of 53.2% YoY demonstrates strong market demand. Excellent gross margin of 65.7% shows strong unit economics and pricing power. ChatGPT: Debt-free balance sheet with $222M cash and strong liquidity (3.6x current ratio). Positive operating and free cash flow with low capex (6.5% FCF margin).
What are the risks of investing in OMDA?
Claude: Currently unprofitable with operating loss of $12.0M and net loss of $12.8M - path to sustained profitability not yet proven. Negative operating margin (-4.6%) and net margin (-4.9%) indicate company is scaling faster than cost structure allows. ChatGPT: Potential revenue growth deceleration as scale increases. Regulatory/reimbursement and payer contract risks affecting revenue visibility.
What is OMDA's revenue and growth?
Omada Health, Inc. reported revenue of $260.2M.
Does OMDA pay dividends?
Omada Health, Inc. does not currently pay dividends.
Where can I find OMDA SEC filings?
Official SEC filings for Omada Health, Inc. (CIK: 0001611115) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OMDA's EPS?
Omada Health, Inc. has a diluted EPS of $-0.35.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is OMDA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Omada Health, Inc. has a BUY rating with 76% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is OMDA stock overvalued or undervalued?
Valuation metrics for OMDA: ROE of -5.6% (sector avg: 16%), net margin of -4.9% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy OMDA stock in 2026?
Our dual AI analysis gives Omada Health, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OMDA's free cash flow?
Omada Health, Inc.'s operating cash flow is $18.3M, with capital expenditures of $1.3M. FCF margin is 6.5%.
How does OMDA compare to other Services stocks?
Vs Services sector averages: Net margin -4.9% (avg: 10%), ROE -5.6% (avg: 16%), current ratio 3.60 (avg: 1.5).